Effect of renal denervation procedure on left ventricular hypertrophy of hypertensive rats and its mechanisms;Efeito da denervação renal na hipertrofia do ventrículo esquerdo de ratos hipertensos e seu mecanismo

Acta Cirurgica Brasileira

Volumn 27, Issue 11, 2012, Pages 815-820

  Jiang, Weihong ^a   Tan, Lihua ^a   Guo, Yunzhong ^a   Li, Xiaogang ^a   Tang, Xiaohong ^a   Yang, Kan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Denervation; Hypertrophy; Kidney; Left Ventricular; Norepinephrine; Rats; Toll Like Receptor 4; Ventricular Remodeling

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; NORADRENALIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE; HEART RATE; HEART VENTRICLE REMODELING; HYPERTENSION; KIDNEY DENERVATION; NONHUMAN; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYMPATHETIC TONE;

ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; DENERVATION; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; KIDNEY; LINEAR MODELS; MYOCARDIUM; NF-KAPPA B; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SYMPATHETIC NERVOUS SYSTEM; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868565360     PISSN: 01028650     EISSN: 16782674     Source Type: Journal    
DOI: 10.1590/S0102-86502012001100012     Document Type: Article

References (17)

1. Dorn GW 2nd. The fuzzy logic of physiological cardiac hypertrophy. Hypertension. 2007;49:962-70.
2. Salles GF, Fiszman R, Cardoso CR, Muxfeldt ES. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension. 2007;50:723-8.
3. Bombelli M, Facchetti R, Carugo S, Madotto F, Arenare F, Quarti-Trevano F, Capra A, Giannattasio C, Dell'Oro R, Grassi G, Sega R, Mancia G. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of office blood pressure values. J Hypertens. 2009;27:2458-64.
4. DiBona GF. Neural control of the kidney: past, present, and future. Hypertension. 2003;41:621-4.
5. Dibona GF. Physiology in perspective: The Wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289:R633-41.
6. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-81.
7. Weinstock M, Gorodetsky E, Kalman R. Renal denervation prevents sodium retention and hypertension in salt-sensitive rabbits wit h genetic baroreflex impairment. Clin Sci (Lond). 1996;90:287-93.
8. Kimura G, Fukuta H. Catheter-based renal sympathetic denervation for treatment of hypertension (J). Nippon Naika Gakkai Zasshi. 2011;100:441-5.
9. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940-6.
10. Prochnau D, Lauten A, Busch M, Kuehnert H, Figulla HR, Surber R. Catheter-based radiofrequency ablation therapy of the renal sympathetic-nerve system for drug resistant hypertension in a patient with end-stage renal disease. Int J Cardiol. 2011;5:234-9.
11. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction. Another model of inflammation? Hypertension. 2004;43:739-45.
12. Tsioufis C, Stougiannos P, Kakkavas A, Toutouza M, Mariolis A, Vlasseros I, Stefanadis C, Kallikazaros I. Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid A in patients with essential hypertension. Am J Cardiol. 2005;96:252-6.
13. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999;104:271-80.
14. Zhang D, Gaussin V, Taffet GE, Belaguli NS, Yamada M, Schwartz RJ, Michael LH, Overbeek PA, Schneider MD. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med. 2000;6:556-63.
15. Purcell NH, Molkentin JD. Is nuclear factor-κB an attractive therapeutic target for treating cardiac hypertrophy. Circulation. 2003;108:638-40.
16. Chrousos GP. The stress response and immune function: clinical implications. Ann NY Acad Sci. 2000;917:38-47.
17. Levick SP, Murray DB, Janicki JS, Brower GL. Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension. 2010;55:270-6.